Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6551836

N#Cc1ccccc1CNc1ccccc1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 4/20 0.43
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ FFAR1 O14842 4/20 0.40
▸ KDM1A O60341 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ CXCR2 P25025 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6550963 0.86 KDM4E (0.49) HIF1AKDM4EGAAMEN1MAPT
Trifluoroacetic Acid SCHEMBL27851317 0.78 KDM1A (0.48) LMNAPOLBKDM4EGAAL3MBTL1
SCHEMBL6700006 0.77 P2RX7 (0.46) POLBKDM4EL3MBTL1MEN1MAPT
SCHEMBL11567016 0.74 MAPT (0.46) LMNAKDM4EGAAL3MBTL1RAB9A
SCHEMBL19921051 0.74 CYP19A1 (0.40) HIF1AKDM4ERAB9AMEN1MAPT
SCHEMBL6925202 0.73 P2RX7 (0.49) KDM4EGAAL3MBTL1FFAR1RAB9A
SCHEMBL30529924 0.73 CYP1A2 (0.59) LMNAPOLBKDM4EGAACXCR2
SCHEMBL16415931 0.73 CYP1A2 (0.59) LMNAPOLBKDM4EGAACXCR2
SCHEMBL20291630 0.72 L3MBTL1 (0.47) LMNAPOLBKDM4EL3MBTL1MEN1
SCHEMBL25796826 0.72 HPGD (0.50) POLBKDM4EGAAL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482929-A1 USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE Aventis Pharma Deutschland GmbH (DE) 2004-12-08 — — EP disclosed
WO-2003072098-A1 USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-09-04 — — WO disclosed
Send feedback